4.7 Article

An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates

期刊

JOURNAL OF PROTEOME RESEARCH
卷 15, 期 6, 页码 2052-2059

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.6b00220

关键词

SMYD2; non-histone substrates; lysine methylation; data integration; pan-methyl lysine antibody

资金

  1. AbbVie
  2. Bayer
  3. Boehringer Ingelheim
  4. Genome Canada through Ontario Genomics Institute [OGI-055]
  5. GlaxoSmithKline
  6. Janssen
  7. Lilly Canada
  8. Novartis Research Foundation
  9. Ontario Ministry of Economic Development and Innovation
  10. Pfizer
  11. Takeda
  12. Wellcome Trust [092809/Z/10/Z]

向作者/读者索取更多资源

Protein methylation is a post-translational modification with important roles in transcriptional regulation and other biological processes, but the enzyme-substrate relationship between the 68 known human protein methyltransferases and the thousands of reported methylation sites is poorly understood. Here, we propose a bioinformatic approach that integrates structural, biochemical, cellular, and proteomic data to identify novel cellular substrates of the lysine methyltransferase SMYD2. Of the 14 novel putative SMYD2 substrates identified by our approach, six were confirmed in cells by immunoprecipitation: MAPT, CCAR2, EEF2, NCOA3, STUB1, and UTP14A. Treatment with the selective SMYD2 inhibitor BAY-598 abrogated the methylation signal, indicating that methylation of these novel substrates was dependent on the catalytic activity of the enzyme. We believe that our integrative approach can be applied to other protein lysine methyltransferases, and help understand how lysine methylation participates in wider signaling processes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据